Avantor (NYSE:AVTR) Coverage Initiated by Analysts at Wells Fargo & Company

Analysts at Wells Fargo & Company began coverage on shares of Avantor (NYSE:AVTR) in a report issued on Tuesday, Benzinga reports. The brokerage set an “overweight” rating and a $30.00 price target on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 17.14% from the stock’s current price.

Several other brokerages have also recently issued reports on AVTR. Robert W. Baird boosted their price target on shares of Avantor from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $30.00 to $23.00 in a report on Wednesday, July 10th. TD Cowen upped their price objective on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Morgan Stanley increased their price target on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Finally, Evercore ISI cut their price target on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $27.40.

Avantor Price Performance

NYSE:AVTR traded up $0.23 during midday trading on Tuesday, hitting $25.61. The company had a trading volume of 2,343,161 shares, compared to its average volume of 6,790,732. Avantor has a 52-week low of $16.63 and a 52-week high of $28.00. The stock’s fifty day moving average price is $23.18 and its 200-day moving average price is $24.08. The company has a market capitalization of $17.40 billion, a PE ratio of 65.67, a P/E/G ratio of 2.71 and a beta of 1.32. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.70 billion. Avantor had a net margin of 5.28% and a return on equity of 12.40%. As a group, research analysts expect that Avantor will post 1.01 earnings per share for the current year.

Hedge Funds Weigh In On Avantor

Institutional investors have recently bought and sold shares of the stock. Versant Capital Management Inc grew its stake in Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares in the last quarter. Blue Trust Inc. grew its stake in Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares in the last quarter. Gladius Capital Management LP purchased a new position in Avantor during the fourth quarter valued at $42,000. Montag A & Associates Inc. purchased a new position in Avantor during the fourth quarter valued at $43,000. Finally, TFO Wealth Partners LLC grew its stake in Avantor by 203,100.0% during the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $46,000 after acquiring an additional 2,031 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.